- Home
- HKPD vs BCAB Comparison
HKPD vs BCAB Comparison
Compare HKPD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HKPD | BCAB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Hong Kong | United States |
| Employees | 27 | N/A |
| Industry | Other Pharmaceuticals | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HKPD | BCAB |
|---|---|---|
| Price | $0.50 | $4.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 84.2K | 29.6K |
| Earning Date | 08-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.12 |
| 52 Week High | $2.74 | $6.52 |
Technical Indicators
Market Signals| Indicator | HKPD | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 49.49 |
| Support Level | $0.45 | $3.92 |
| Resistance Level | $0.71 | $6.33 |
| Average True Range (ATR) | 0.07 | 0.44 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 29.67 | 42.50 |
Price Performance
Historical ComparisonAbout HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.